Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5E1QZ
|
|||
| Drug Name |
BNT212
|
|||
| Drug Type |
Cell therapy
|
|||
| Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Preclinical | [1] | |
| Company |
BIONTECH
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Claudin-18 (CLDN18) | Target Info | . | [1] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Tight junction | ||||
| Leukocyte transendothelial migration | ||||
| Hepatitis C | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Reactome | Tight junction interactions | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Biontech | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.